Bio-Rad Laboratories, Inc. (BIO) Q3 2022 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET

Company Participants

Edward Chung - VP, IR

Ilan Daskal - EVP & CFO

Andrew Last - EVP & COO

Norman Schwartz - Chairman, CEO & President

Dara Wright - EVP & President, Clinical Diagnostics Group

Simon May - EVP & President, the Life Science Group

Conference Call Participants

Patrick Donnelly - Citigroup

Brandon Couillard - Jefferies

Daniel Leonard - Crédit Suisse

Jack Meehan - Nephron Research

Operator

Good evening, and thank you for attending today's Bio-Rad Laboratories 2022 Earnings Results Conference Call. My name is Daniel, and I will be your moderator for today's call. [Operator Instructions]. I would now like to pass the conference over to our host, Edward Chung, Head of Investor Relations of Bio-Rad. Edward, please proceed.

Edward Chung

Thanks, Daniel. Good afternoon, and thank you all for joining us. Today, we will review the third quarter 2022 financial results and provide an update on key business trends for Bio-Rad.

On the call with me today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Simon May, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group.

Before we begin our review, I'd like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties.

Included in these forward-looking statements are commentary regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations and steps Bio-Rad is taking in response to the pandemic. Our actual results may differ materially from these plans and expectations, and the impact and duration of the COVID-19 pandemic is unknown.

You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business.

The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP net income and diluted earnings per share, which are financial measures that are not defined under Generally Accepted Accounting Principles.